

(Print or Type Responses)

Person \*

1. Name and Address of Reporting

DeSimone Colleen Elizabeth

## UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL					
OMB	3235-				
Number:	0104				
Estimated average					
burden hours pe	r				
response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statement

(Month/Day/Year)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Syros Pharmaceuticals, Inc. [SYRS]

Desimone Concent Enzacet	00/2	28/2017							
(Last) (First) (Mid 620 MEMORIAL DRIVE, SI 300	ldle)	26/2017		erson(s) to l	ip of Reporting (ssuer all applicable)	Filed(Mon	endment, Date Original th/Day/Year)		
(Street)			_	Director X Officer (g			6. Individual or Joint/Group		
CAMBRIDGE, MA 02139				title below) below) Principal Accounting Officer		Filing(Che icer _X_Form fi	Filing(Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting		
(City) (State) (Z	ip)	Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security (Instr. 4)			mount of Se eficially Ow r. 4)			4. Nature of Indi Ownership (Instr. 5)	rect Beneficial		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  SEC 1473 (7-02)  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security 2. Da (Instr. 4) Expir		e Exercisable and 3. Tit ation Date Security		d Amount of Underlying Security	of 4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	Amount of Number of Shares		e Security: Direct (D) or Indirect (I) (Instr. 5)			
Stock Option (right to buy)	(1)	06/08/2025	Common Stock	13,566	\$ 3.04	D			
Stock Option (right to buy)	(2)	12/22/2025	Common Stock	2,666	\$ 9.08	D			
Stock Option (right to buy)	(3)	02/09/2027	Common Stock	21,800	\$ 10.9	D			

Relationships

Principal Accounting Officer

Other

Officer

Director 10% Owner

## **Signatures**

**Reporting Owners** 

DeSimone Colleen Elizabeth

CAMBRIDGE, MA 02139

Reporting Owner Name / Address

620 MEMORIAL DRIVE, SUITE 300

/s/ Colleen E. DeSimone	10/06/2017
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option is exercisable as to 2,454 shares and becomes exercisable as to the remaining 11,112 shares in equal monthly installments on the last day of each month until April 27, 2019.
- (2) This option is exercisable as to 1,221 shares and becomes exercisable as to the remaining 1,445 shares in equal monthly installments on the last day of each month until October 21, 2019.
- This option becomes exercisable as to 25% of the shares underlying the option on February 10, 2018, with the remainder becoming exercisable in equal monthly installments of 2.0833% of the shares underlying the option at the end of each successive month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.